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Objectives









Describe federal and state laws pertaining to the prescribing and
dispensing of opioid controlled medications
Discuss methods of validating a prescription for therapeutic
appropriateness and approaches for the detection of prescriptions
that are not medically appropriate or have been furnished by
fraudulent means
Review and assess prescriptions for appropriateness, quantity
limitations and other requirements for opioids in the treatment of
acute and chronic management of pain
Discuss the purpose and function of the Florida Prescription Drug
Monitoring Program (PDMP) E-FORCSE in identifying potential
diversion of controlled substances (CS)
Provide comprehensive patient education on overdose symptoms,
information on available treatment resources for opioid
dependence, addiction, misuse or abuse, as well as naloxone
counseling (storage, disposal, potential drug interactions, side
effects)

Schedules of CS’s
Schedule
C-I

C-II

Potential for Abuse

Examples

High – Medical use currently not
accepted in the US

•
•
•

Heroin
Lysergic acid diethylamide (LSD)
Ecstasy

High – May lead to severe
psychological or physical dependence

•
•
•
•
•
•
•

Hydromorphone
Methadone
Meperidine
Oxycodone
Fentanyl
Amphetamines
Methylphenidate

•
•

C-III

Less than C-I or C-II’s – May lead to
low-moderate psychological or
physical dependence

•
•
•

Combination products containing <15 mg
of hydrocodone per dosage unit
Combination products containing ≤90 mg
of codeine
Buprenorphine products
Ketamine
Anabolic steroids

C-IV

Low

•

Benzodiazepines

C-V

Low

•

Cough preparations containing ≤200 mg of
codeine per 100 mL or per 100 g

Background


An average of 130 Americans die every day from an

opioid overdose




In 2018:


2 million people had an opioid use disorder



~ 10.3 million people aged ≥12 misused opioids

The United States Department of Health and Human
Services (HHS) developed a 5-point comprehensive
strategy to address opioid abuse, dependence, and

overdose

National Institute on Drub Abuse: Florida Opioid Summary

HHS 5-point
Comprehensive Strategy

National Institute on Drub Abuse: Florida Opioid Summary

Florida Opioid Prescribing
Rates

60.9 vs 58.7

National Institute on Drub Abuse: Florida Opioid Summary

Florida Drug Overdose
Deaths

National Institute on Drub Abuse: Florida Opioid Summary

CDC Combats Opioid Crisis
Enhanced State Opioid
Overdose Surveillance
(ESOOS) Program
 Captures different types of
data for both fatal and
nonfatal overdoses







2016: 12 states were funded
2017: additional 20 states and
the District of Columbia were
added

Every four months, ESOOSfunded states report overdose
data to CDC

www.cdc.gov/drugoverdose/data/prescribing/overdose-death-urbanicity

ESOOS Program


Data collected via emergency department (ED)
hospital billing system and synchronized surveillance
data




Utilize standard diagnostics codes that categorize if the
visit was for an overdose

Objective is to improve the timeliness of fatal and
nonfatal opioid overdose data for action and response





Establish an early warning system
Integrates data from death certificates and medical
investigations
Shares findings with state and national stakeholders

www.cdc.gov/drugoverdose/data/prescribing/overdose-death-urbanicity

ESOOS Program Success


Identified 700 deaths involving fentanyl analogs
across 10 of the ESOOS states from July to
December 2016



Reported findings on opioid overdoses treated in
the EDs in 16 of the ESOOS states from July 2016
through September 2017, showed that ED visits
for opioid overdoses increased 30% in all parts of
the United States

www.cdc.gov/drugoverdose/data/prescribing/overdose-death-urbanicity

History
↑ in OD deaths
due to ↑
prescribing
1970

Enactment of the
CSA

1990

↑ in OD deaths
due to heroin
2010

2010

Amendment to CSA
allows for E-prescribing
of opioids

HHS enacts 5-point
strategy to combat
opioid epidemic

2013

2017

House Bill 21

↑ in OD deaths due
to use of synthetic
opioids

CSA: controlled substance act; OD: overdose; HHS: Health and Human Services

2018

Federal Controlled
Substance Laws

Controlled Substance Act


The CSA provides a mechanism for substances to be
controlled



Establishes federal requirements regarding both illicit
and licit CS



Designed to function in tandem with state controlled
substance laws to make certain that pharmaceutical
CS are prescribed, administered, and dispensed for a
legitimate medical purpose

Diversion Control Division: Title 21 United States Code (USC) Controlled Substance Act

Controlled Substance Act

Manufacturers

Closed
System

Doctors

Patients

Diversion Control Division: Title 21 United States Code (USC) Controlled Substance Act

Distributors

Pharmacies

Controlled Substance Act


The Drug Enforcement Administration (DEA)
responsibility in regards to pharmaceutical CS:


Prevent diversion and abuse of CS while ensuring
appropriate and uninterrupted supply to meet the

patient’s legitimate medical, scientific, and research
needs.

Diversion Control Division: Title 21 United States Code (USC) Controlled Substance Act

Valid Prescription
Requirements


Prescription: an order for a medication which is
dispensed to or for an ultimate user



An Rx for a CS must be dated and signed on the date
when it was issued



Must include:
Patient’s full name and address

Medication name

Practitioner’s full name,

Strength and dosage form

address, and DEA registration

Quantity prescribed

number

Directions for use
Number of refills authorized

United States Department of Justice: Pharmacist’s Manual CS Act

Valid Prescription
Requirements


Rx must be written in ink or typewritten and manually
signed by the practitioner on the date when issued



An Rx for a CS may only be issued by a physician,
dentist, podiatrist, veterinarian, or mid-level
practitioner acting in the usual course of professional
practice and for a legitimate medical purpose

United States Department of Justice: Pharmacist’s Manual CS Act

Valid Prescription
Requirements


Pharmacist’s role in validating CS prescriptions:


Responsible to exercise sound professional judgment

when making a determination about the legitimacy of an
Rx prior to dispensing medication


Responsible for ensuring Rx has been issued by an
appropriately registered practitioner

United States Department of Justice: Pharmacist’s Manual CS Act

Electronic Prescriptions


The DEA published an interim final rule for electronic
Rxs for CS



Became effective June 1st, 2010



Provide practitioners with the option of writing Rxs for
CS electronically



Allow pharmacies to receive, dispense, and archive

these electronic Rxs

United States Department of Justice: Pharmacist’s Manual CS Act

C-II Substances
Requirements

C-II Substances


Require a written Rx which must be manually signed by the
practitioner or an electronic Rx meeting all of the DEA’s
requirements



There is no federal time limit within which a C-II Rx must be
filled after being signed by the practitioner



No federal limits with respect to the quantitates of medications
dispensed via an Rx



Oral orders are only permitted in emergent situations



Refills are prohibited

United States Department of Justice: Pharmacist’s Manual CS Act

C-II Substances


Up to a 90-day supply of a C-II may be dispensed under the
following conditions:


Each Rx must be issued on a separate prescription blank



Must be issued for a legitimate medical purpose by an
individual practicing under the course of professional practice



Rx must provide written instructions indicating the earliest
date on which a pharmacy may fill each Rx



Allowed under State Laws



Practitioner complies fully with all requirements under the CSA
and state laws

United States Department of Justice: Pharmacist’s Manual CS Act

C-II Substances


Rxs may be transmitted to the pharmacy by facsimile in
order to expedite the filling of an Rx



The original Rx must be presented to the RPh and
verified against the facsimile at the time the CS is

dispensed

United States Department of Justice: Pharmacist’s Manual CS Act

C-II Substances


Exceptions for C-II facsimile prescriptions:


C-II narcotic CS to be compounded for the direct

administration to a patient by parenteral, IV, IM, SQ, or
intraspinal infusion


C-II’s for residents of Long Term Care Facilities



C-II’s for a patient enrolled in a hospice program

United States Department of Justice: Pharmacist’s Manual CS Act

C-II Dispensing
Requirements


Required information for Rx labels:









Date of filling
Pharmacy name and address
Rx number
Patient’s name
Prescriber’s name
Directions for use and cautionary statements
“CAUTION: Federal law prohibits the transfer of this
drug to any person other than the patient for whom it
was prescribed”

United States Department of Justice: Pharmacist’s Manual CS Act

C-II Dispensing
Requirements


C-II’s may only be dispensed pursuant to a written Rx
signed by the practitioner with the exception of an
emergency situation



Emergency dispensing: immediate administration of

the medication is necessary for proper treatment of
the intended ultimate user and no alternative
treatment is available

United States Department of Justice: Pharmacist’s Manual CS Act

C-II Emergency
Dispensing


Prescriber must provide a written and signed Rx to the
pharmacy within seven days of Rx being phoned in and

must contain “authorization for emergency dispensing”
written with the date of the oral order


Rx must be limited to the amount needed to treat the
patient during the emergency



Order must be immediately reduced to writing by the RPh

and contain all information with the exception of the
prescriber’s signature

United States Department of Justice: Pharmacist’s Manual CS Act

C-II Partial Dispensing


C-II’s may be partially dispensed if the RPh is unable

to supply the full quantity


Remaining portion may be dispensed within 72 hours of
the first partial dispensing



RPh must notify prescribing practitioner if remaining
portion cannot be filled within 72 hours



RPh must note quantity supplied on the front of the
written Rx

United States Department of Justice: Pharmacist’s Manual CS Act

CIII-V Substances
Requirements

CIII-V Substances


Rx may be received via facsimile as long as the

practitioner has manually signed the Rx


Rx may be dispensed pursuant to an oral Rx made by
an individual practitioner and reduced to writing by
the RPh



May be transferred to another DEA registered

pharmacy for the purpose of refill dispensing between
pharmacies on a one time basis
United States Department of Justice: Pharmacist’s Manual CS Act

CIII-V Substances


Pharmacies sharing a real-time, on-line database may

transfer up to the maximum refills permitted by law


Transfer of CIII-V must be communicated between
two licensed RPhs

United States Department of Justice: Pharmacist’s Manual CS Act

Dispensing of C-III & C-IV
Refills


C-III’s and C-IV’s may be refilled up to 5 times within
6 months after the date of issue



Required information to be recorded on the back of
Rx:


RPh’s initials



Date the Rx was refilled



Amount of medication dispensed on the refill

United States Department of Justice: Pharmacist’s Manual CS Act

Florida Controlled
Substance Laws

Standards of Practice


The Board of Pharmacy recognizes that it is

important for the patients to be able to fill valid
Rxs for CS


RPhs should not fear disciplinary action for

dispensing CS for a legitimate medical purpose
in the usual course of professional practice


Every patient’s situation is unique and Rxs for
CS shall be reviewed accordingly

Florida Statue 64B16-27.831

Definitions – FL Law


Valid Rx– An Rx is valid when it is based
on a practitioner-patient relationship and

when it has been issued for a legitimate
medical purpose



Invalid Rx– An Rx is invalid if the RPh
knows or has reason to know that the Rx
was not issued for a legitimate medical
purpose

Florida Statue 64B16-27.831

House Bill 21


Effective July 1st, 2018



Florida specific



Objective is to increase regulation, training, and
reporting required when CS are prescribed and

dispensed


E-FORCSE®*



Prescribing limitations

*Electronic-Florida Online Reporting of Controlled Substance Evaluation Program
House Bill No. 21: Chapter 2018-13.p1-106

Defining Pain
Acute Pain
Normal, predicted,
physiological, and timelimited response to an
adverse chemical, thermal,
or mechanical stimulus
associated with surgery,
trauma, or acute illness

House Bill No. 21: Chapter 2018-13.p1-106

Non-acute or Chronic Pain
Cancer, terminal condition,
palliative care or serious traumatic
injury with an Injury Severity Score
(ISS) ≥9
• Chronic nonmalignant pain
persisting beyond usual course of
disease or injury OR pain persisting
>90 days after surgery
• Requires treatment plan
• Patients entered in CS
agreement with prescriber
• Patients must be seen at least
every 3 months
• Patient may only have a single
provider
•

Application
Acute Pain

Non-acute Pain

• Limits an Rx for an opioid
• Prescriber must indicate
listed in C-II to 3 days
“NONACUTE PAIN” on an Rx for
• Limit may be increased to 7
a C-II medication
days if determined to be
• Patients treated for a traumatic
medically necessary
injury with an ISS of ≥9 must
• Prescriber must have
be concurrently prescribed an
“ACUTE PAIN EXCEPTION”
emergency opioid antagonist
on the Rx
• If this is not received, RPh
• Limits the dispensing of a
should follow standard policy
CII-III medication in
and procedures and contact
connection to a surgical
prescriber
procedure to a 14 day supply
• Any changes should be
• Limits do not apply to C-II
promptly reduced to writing
medications for treatment of
and properly annotated
addiction
House Bill No. 21: Chapter 2018-13.p1-106

Prescription Pads Sample

Assessing for Prescription
Appropriateness

Deciding for Prescription
Appropriateness


Rx looks authentic and has all the information required
by law



Perform prospective Drug Utilization Review



Assess drug, dose and duration



Review the patient’s medication profile in your
computer



Review the PDMP report

Legible Prescription


A written Rx for a CS must have the quantity of the
medication prescribed in both textual (one, two,
three, etc) and numerical (1,2,3, etc) formats



Must be dated in one of the following ways:

Florida Statue 456.42



Numerical month/day/year format (ex: 1/1/2016)



Abbreviated month written out (ex: Jan. 1, 2016)



Month written out in whole (ex: January 1, 2016)

Deciding for Prescription
Appropriateness


Speak with the prescriber



Previous experience


Converse and observe the behavior of the patient



Patient’s medical history



Clinical appropriateness and safety


Quantity limitations and other requirements in the
treatment of acute and chronic management of pain

Validating a Prescription

Corresponding Responsibility


The responsibility for the proper prescribing and dispensing of CS
is upon the prescribing practitioner, but a corresponding
responsibility rests with the RPh who fills the Rx



The law further states that any individual knowingly dispensing an
invalid Rx for a CS will be subject to criminal penalties and
administrative sanctions

CFR Section 1306.04

Validating a Prescription


The process implemented by the RPh to determine that

the Rx was issued for a legitimate medical purpose


Each Rx may require a different validation process and
no singular process can be applied each situation



A concern with validity does not mean the Rx should
not be filled

Florida Statue 64B16-27.831

Validating a Prescription


When validating an Rx:


Neither a person or licensee must interfere with the
exercise of the RPh’s independent professional judgment



Communication with the patient should not be overheard
by others



If the RPh determines that concerns with validity cannot

be resolved, the RPh must refuse to fill

Florida Statue 64B16-27.831

Refusal of CS Prescription


Before the refusal of an Rx, the RPh shall do the
following:


Communicate with the patient or the patient’s
representative



Contact the prescriber or the prescriber’s agent



Access the PDMP to acquire information

Florida Statue 64B16-27.831

Duty to Report


If an RPh believes that a prescriber is involved in the
diversion of CS, he/she must report the prescriber to the
Department of Health



This can be reported online at:


www.floridahealth.gov/licensing-and-regulation/enforcement/index.html

Florida Statue 64B16-27.831

Federal and State
Requirements for CII-CV
CII
Refills

Transfer of Rx
Between
Pharmacies

Facsimile Rx
Allowed

CIII-CV

No refills allowed

5 within 6 months from date
written

No transfers permitted

1 allowed (may transfer additional
times to the maximum if within
same common database)

May be received in
preparation, but original hardcopy is required
Exceptions:
• Narcotic compounded for
direct administration to
patient
• LTCF/Hospice Patients

Yes

Federal and State
Requirements for CII-CV
CII
Electronic Rx
Allowed

CIII-CV

Yes

Yes

Partial Fills
Allowed

Yes
• Remainder required within
72 hrs
• For terminally ill patients and
LTCF patients, Rx is good for
60 days

Yes
• No restrictions as long as
within total quantity and 6
month limitation

Emergency
Dispensing

Limited to the amount needed
to treat the patient
• Dispensing is limited to a 72hour supply

Yes

Expiration Date

No expiration (FL law imposes 1
year expiration on all Rx)

6 months from date written

Fraudulent Prescriptions




Usually patients tend to come at the end of the day


RPh is extremely busy



Prescriber’s office is closed

Most drug abusers seek areas where communication

and cooperation between healthcare professionals is
minimal


The RPh should become familiar with CS that are
popularly abused and resold on the streets

DEA Guidelines to Prescription Fraud. Florida Board of Pharmacy.
Prescription Drug Diversion: Fraudulent Tactics Utilized in the Community Pharmacy.

Types of Fraudulent
Prescriptions


Quantity altered: change “10” to “100” or “10” to “40”



Adding refills or altering the directions



Adding an additional medication to a legal Rx




Changing medication: adding “ES” to Vicodin

Individuals calling in their own Rx


Forging call back number and using fictitious patient or
physicians name and addresses

DEA Guidelines to Prescription Fraud. Florida Board of Pharmacy.
Prescription Drug Diversion: Fraudulent Tactics Utilized in the Community Pharmacy.

Fraudulent Prescriptions:
Things to Look For


Rx looks “too good”. The prescriber’s handwriting is too legible



Quantities, directions, or dosages differ from usual medical usage



Rx does not comply with acceptable standard abbreviations
(directions that are written out)



Rx appears to be photocopied



Directions are written in full with no abbreviations



Rx is written in different color inks or written in different
handwriting

Diversion Techniques and
Signs by Patients


Changes in personality and/or appearance



Claiming multiple allergies to alternative medications



Aggressively complaining about a need for a
medication


Uses medical terminology with respect to their pain



Requests specific generics or brands



No clear diagnosis from the physician



Frequently ask for early refills

Diversion Techniques by
Prescribers


Patients traveling long distances to see practitioner



Practitioner prescribing excessive quantities of CS
relative to the medical condition



Multiple medications within the same category or

medication cocktails being prescribed


Examples: Narcotic pain killer + benzodiazepine + sleeping pill +
codeine containing cough syrup + carisoprodol or any other combination



Health care professionals prescribing outside their
scope of practice

Diversion Techniques by
Prescribers


Physician’s note and diagnosis are similar for every
patient






Lack of individualization

Practitioner ignoring signs of abuse


Patient’s appearance



Requesting for specific CS



Practitioner ignoring toxicology reports

Beware of nurses and non-medical staff calling in oral
Rxs

Motivation for Diversion


Money – financial gain



Fear


Stop blackmail



Sexual favors



Keep business going/co-independency



Personal Use – self abuse

Pharmacist Checklist to
Prevent Diversion


Type of medication prescribed (number of CNS
depressants and stimulants)



Duplicate therapy or duplicate therapeutic classes



Strengths, quantity, and days supply of medication
prescribed



Number of physicians the patient is seeing



Escalating doses, quantities, and/or strengths



Method of payment by patient



Look for documentation in patient record

®
E-FORCSE
Overview
What is it?
• Electronic
systems that
digitally store,
monitor, and
analyze CS
dispensing
information

E-FORCSE® Florida Department of Health

What data is
collected?

Who can
access data?

• Patient info
• Prescriber info
• Dispenser info
• CII-V
medications

• Prescribers
• RPh
• Law
enforcement
• State medical
boards

Structure of Legislation

E-FORCSE® Florida Department of Health

Data Reported to
®
E-FORCSE


Prescribing practitioner name, federal DEA registration
number, National Provider Identification (NPI), and date
Rx written



Date Rx was filled and the method of payment



Name, address, telephone number and date of birth
(DOB) of patient for whom the Rx was written

Florida Statute 893.055(3)(a)(1-8)

Data Reported to
E-FORCSE®


Name, national drug code, quantity, and strength of CS



Name, federal DEA registration number, and address of
the pharmacy/location from which the CS was dispensed



Name of pharmacy or practitioner (other than an RPh)
dispensing the CS and the practitioner’s NPI identifier



Other appropriate identifying information as determined

by department rule

Florida Statute 893.055(3)(a)(1-8)

Healthcare Professional
Responsibilities


Must report to PDMP each time a CS in CII-V is dispensed


All patients ≥16



Including internet and mail order pharmacies and dispensing

healthcare practitioners


Report as soon thereafter as possible but no later than
close of next business day after Rx dispensed


Exceptions apply



Dispenser must file a zero report if there are no

transactions to report for that day
Florida Statute 893.055(3)(a)(1-8)

Zero Reports
https://pmpclearinghouse.net
 Confirmation email is sent to submitter


Healthcare Professional
Responsibilities


Those that never dispense CS in or into Florida are

not required to report to E-FORCSE®


Must notify E-FORCSE® in writing by submitting a
“Notification of Exemption from Reporting Form”


Must be renewed biennially on or before February 28 in
odd years



http://www.floridahealth.gov/statistics-and-data/eforcse/_documents/waiver-form-2014apr-distributed.pdf

Florida Statute 893.055(3)(a)(1-8)

Statutory Exceptions


Patients <16



C-V non-opioid medications



System is not operational



Requestor has technological or electrical failure


Prescriber or dispenser shall document the reason
for not consulting PDMP in patient’s record



Florida Statute 893.0551(8)(2)(b)

Shall not prescribe/dispense ≥3-day supply

Reporting Exemptions




All acts of administration:


Directly to patient



Hospital



Nursing home, assisted-care facility, or rehabilitation center



Ambulatory surgical center



Hospice



Intermediate care facility for the disabled

Dispensing in the Florida Department of Corrections or
ED of a licensed hospital

E-FORCSE® Florida Department of Health; S. 893.055(2)(a), F.S.

Emergency Suspension
from Reporting


A reporting suspension waiver will be granted for the
seven day reporting period



Once the state of emergency has been lifted, the

dispenser must report the backlog of data as soon as
possible to bring reporting current

DH8013-PDMP, 07/15Ïule 64K-1.004, F.A.C.

Reporting Noncompliance


A dispenser who willfully and knowingly fails to report

the dispensing of a CS medication, as required by
section 893.055, F.S., commits a misdemeanor of
the first degree


Florida Statute 775.082-775.083

Punishable by 775.082 or 775.083, F.S.

Utilizing

®
E-FORCSE

Pharmacist Requirements


An RPh must verify the identity of an individual

prior to dispensing a CS medication


Proper identification is issued by a state or the Federal
Government containing the person’s photograph, printed
name, and signature or a document considered
acceptable under 8 C.F.R. s. 274a.2(b)(1)(v)(A) and (B)

8 C.F.R. s. 274a.2(b)(1)(v)(A) and (B)

Assessment of Rx using
E-FORCSE®


PDMP reports are only as good as they are entered



Potential errors may include:


Rx filled but not picked up yet



Incorrect day supply



Wrong date written



Wrong doctor



Patient name misspelled or multiple last names



Wrong DOB or address

E-FORCSE® Florida Department of Health

Assessment of Rx using
E-FORCSE®


If something does not look correct in PDMP, call the

pharmacy who filled the Rx or prescriber in order to
verify


Example: An RPh looks at the PDMP and sees the patient
had an Rx for alprazolam 2 mg, #300, one tab BID
• Steps to take: call pharmacy who filled Rx and verify the
information found on PDMP

E-FORCSE® Florida Department of Health

PDMP Checklist


Type of medications prescribed



Duplicate therapy



Strengths and quantities



Number of physicians the patient is seeing



Number of pharmacies the patient is using



Is the patient using urgent care centers, convenience clinics,
EDs, and/or dentists to obtain CS medications?



Are patients getting medications filled early?



Are the doses, quantities, and/or strengths escalating?

E-FORCSE® Florida Department of Health

Opioid Overdose,
Prevention and
Management

Overdose
 On average, 130 Americans
die each day from an opioid
overdose
 Between 1999-2017, there
were ~400,000 opioid
overdose deaths
 1990’s: increased
prescribing of opioids
 2010: rise in heroin
overdose deaths
 2013: synthetic opioid
overdose deaths,
specifically involving
fentanyl
Opioid Overdose. Centers for Disease Control and Prevention. Updated December 19, 2018. Accessed December 20, 2019.

Pathophysiology of Overdose

 Several receptors mediate the effects of opioids
• Mu  analgesia, euphoria, constipation, respiratory depression, miosis
• Kappa  analgesia, diuresis, dysphoria
• Delta  analgesia, convulsions, anxiolysis

 Opioid receptors are located in both the central and peripheral
nervous system (brain, spinal cord and GI tract)
Schiller EY, Mechanic OJ. Opioid Overdose. StatPearls Publishing. 2019. Updated Mar 2, 2019.

Opioid Mechanism of Action


Potent agonism of the mu
receptor by opioids results
in a release of dopamine,
blockade of pain
transmission and a euphoric
sensation via the reward
pathway



In the case of overdose, the
opioid receptors located in
the medulla are
overwhelmed and can
suppress respiratory drive
to the point of cessation

Opioid Pharmacokinetics
 Normally, opioids undergo
first order elimination
 When opioid receptors are
saturated, elimination is
converted to zero order
kinetics and small dose
increases can change
plasma concentration
immensely

Schiller EY, Mechanic OJ. Opioid Overdose. StatPearls Publishing. 2019. Updated Mar 2, 2019.

Risk Factors for Overdose


Individuals who are dependent on opioids for chronic pain



Taking increasing doses of opioids for pain management



High-dose opioids (> 50 MME/d)



Concomitant severe medical or psychiatric conditions (depression,

HIV, lung/liver disease)


Combining opioids with alcohol or other sedatives



Male gender



Younger age



Household members taking opioids



History of injection drug use

Schiller EY, Mechanic OJ. Opioid Overdose. StatPearls Publishing. 2019. Updated Mar 2, 2019.

Morphine Milligram Equivalents
High-dose opioids (> 50 MME/d) increase a patients risk of overdose

•

2 mg PO q4h = 48 MME

•
•

15 mg oxycodone BID = 45 MME
30 mg oxycodone BID = 90 MME

•
•

Percocet® 5/325 QID = 30 MME
Percocet® 10/325 QID = 60 MME

https://www.google.com/search?q=morphine+equivalents&rlz=1C1CHBF_enUS851US851&sxsrf=ACYBGNTGkCV6ihirn3pf1BsrwN5V3_NNDQ:1577560504349&source=lnms&tbm=isch&sa=X&ved=2ah
UKEwi4wOTrhtnmAhVqhOAKHXKLB1IQ_AUoAXoECAsQAw&biw=1368&bih=721&dpr=2#imgrc=0VJWrQ98axfilM:

Naloxone

Mechanism of Action

 Naloxone is a pure opioid antagonist that competes and displaces opioids at opioid
receptor sites
 Has stronger affinity than opioids at all opioid receptor subtypes, but most notably at
the mu receptor
 Specifically designed to only reverse overdose – while it still binds to opioid receptors,
it will not produce a “high” or have any opioid-like effects
 Naloxone has no effect if opioids are not present
Naloxone for Opioid Overdose: What Pharmacists Should Know. PharmacyTimes.Updated June 2016. Accessed December 20, 2019.

Naloxone Administration


Naloxone is available to be administered via 2 routes:
 Intranasal
A. Narcan® nasal spray
B. Naloxone nasal spray with atomizer


Intramuscular
C. Evzio® auto-injector
D. Naloxone injectable – IM or SC

Naloxone Dosing
Products

Dose

Narcan® Nasal Spray

4 mg/0.1 mL

Naloxone Nasal Spray
with Atomizer

2 mg/2 mL

Evzio® Auto-injector

2 mg/0.4 mL

Naloxone for injection

0.4 mg/1 mL

Naloxone (Narcan®) Nasal Spray
 Requires no assembly, very simple
to use
 Peel, Place, Press
 Peel back the tab to remove the
device from the packaging
 Hold nasal spray with your thumb on
the bottom, and your middle and index
fingers on either side of the nozzle
 Tilt the person’s head back, support
their head and place the tip of the
nozzle into 1 nostril until your fingers
touch the patient’s nose
 Press the plunger firmly to administer
the full dose and call 911
 Repeat with the other nostril if the
person does not respond in 2-3
minutes

Family Health Centers of San Diego. Opioid Safety. https://www.fhcsd.org/opioid-safety/. Accessed December 20, 2019.

Naloxone Nasal Spray
 Requires assembly
 Pop off the yellow caps from either end
of the syringe
 Screw on the nasal atomizer to the tip of
the syringe
 Remove the colored cap from the
naloxone and insert into the barrel of the
syringe, gently screwing them together
 Insert the white cone into the nostril and
give a short, strong push on the end of
the naloxone to administer
 One half of the naloxone capsule
should be administered into each
nostril
 Repeat the above if the patient does not
respond in 3 minutes

Family Health Centers of San Diego. Opioid Safety. https://www.fhcsd.org/opioid-safety/. Accessed December 20, 2019.

Naloxone (IM)
 Administering injectable naloxone
(either IM or SC) requires assembly
 First, remove the cap from the naloxone
vial and uncover the needle
 Insert the needle into the rubber stopper
 Invert the vial to withdrawal the full
contents (1 mL) into the syringe
 Inject naloxone into either the deltoid or
quadricep muscle
 Naloxone can be injected through the
clothing!
 Repeat the dose if the patient does not
respond within 3-5 minutes
Family Health Centers of San Diego. Opioid Safety. https://www.fhcsd.org/opioid-safety/. Accessed December 20, 2019.

Naloxone (Evzio®)
 No assembly and very simple to use
 The device is equipped with a voice instruction
system to guide the user through the entire
administration process
 Steps for use:
 The auto-injector should be pulled from the
outer case
 Firmly remove the red safety guard (the needle
is housed within the black base)
 Place the black end of the device against the
middle of the outer thigh, press firmly and hold
in place for 5 seconds (the needle will retract
into the device when the dose is given)
 Can be administered through clothing
 If no response in 2-3 minutes, repeat the dose
using a second auto-injector
 Note: the Evzio® device makes a distinct
clicking/hissing sound on administration – this is
normal and indicates the device is working properly

Evzio. How to Use Evzio. https://evzio.com/patient/how-to-use-evzio/. Accessed December 20, 2019.

Storage and Disposal


Storage






Naloxone should be stored at room temperature in its original
packaging
Should be kept away from children/pets, but always in a place
that is quickly and easily accessible
Do not assemble naloxone until ready to administer, when
applicable

 Disposal

• For intranasal dosage forms, the used
naloxone can be discarded with other solid
waste
• For injectable dosage forms, the used
naloxone should be discarded of in a sharps
container (this can be an empty laundry
detergent bottle or thick/hard plastic
container)

Adapt Pharma Incorporation. Narcan (naloxone) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208411lbl.pdf. Accessed December 20, 2019.

Drug Interactions and Side
Effects


DDI’s




Due to its action as an opioid antagonist, naloxone will have
an interaction with any drug considered an opioid

Side effects









Sudden opioid withdrawal symptoms:
Body aches
Diarrhea
Tachycardia
Fever
Runny nose
Sneezing







Goose bumps
Sweating
Yawning
Nausea/vomiting
Nervousness







Restlessness
Shivering
Abdominal cramps
Weakness
Hypertension

Adapt Pharma Incorporation. Narcan (naloxone) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208411lbl.pdf. Accessed December 20, 2019.

Who Should be Given a
Prescription for Naloxone?


Title XXXII, Ch. 456.44 of Florida Pharmacy Law states:




EMERGENCY OPIOID ANTAGONIST.—For the treatment of pain related to a
traumatic injury with an Injury Severity Score of 9 or greater, a
prescriber who prescribes a Schedule II controlled substance listed in
s. 893.03 or 21 U.S.C. s. 812 must concurrently prescribe an
emergency opioid antagonist, as defined in s. 381.887(1).

Patients who are considered to be “high risk” for opioid overdose:










History of overdose or substance abuse
High opioid doses (> 50 MME/d)
Concurrent benzodiazepine use
Sleep apnea
Pregnancy
Renal/hepatic disease
> 65 years old
Concomitant mental health conditions

Dreiling J. The Validation of Controlled Drug Prescriptions in Florida. https://s3.amazonaws.com/EliteCME_WebSite_2013/f/pdf/RPFL02VCI18.pdf. Accessed December 20, 2019.

Recognizing an Overdose


The “opioid overdose triad” is a combination of 3 signs and
symptoms that can be used to identify an opioid overdose
 Pinpoint pupils
 Unconsciousness
 Respiratory depression (slow, shallow breathing)



Other signs to look for include:
 Skin, lips and fingernails will be a bluish/purple color
 Choking sounds, or a snore-like gurgling noise
 Vomiting
 Slowed heart rate
 Body is limp



The combination of opioids with alcohol and other CNS
depressants increases the risk of death due to an overdose

Dreiling J. The Validation of Controlled Drug Prescriptions in Florida. https://s3.amazonaws.com/EliteCME_WebSite_2013/f/pdf/RPFL02VCI18.pdf. Accessed December 20, 2019.

How to Tell the Difference



It can sometimes be unclear whether a person is overdosing
or is just extremely high
Always err on the side of caution and respond as if the
person is experiencing an overdose
High

•
•
•
•
•



Pinpoint pupils
Muscles are droopy/limp
“Nodding out”
Slurred speech
Might seem disoriented, but
will respond to outside
stimulus (noises, agitation)

Overdosing
•
•
•
•
•

Pinpoint pupils
Loss of consciousness
Awake but unable to speak
Skin/nail/lip color changes
Unresponsive

Whether or not the patient is responsive will help to
determine if the patient is high versus overdosing

Recognizing Opioid Overdose. Harm Reduction Coalition. https://harmreduction.org/issues/overdose-prevention/overview/overdose-basics/recognizing-opioid-overdose/. Accessed December 20, 2019.

Responding to an Overdose

Call 911

Perform
CPR

Administer
naloxone

Stay until
help
arrives

Responding to an Overdose


1. Call 911




Opioid overdoses will still require professional medical
assistance even if naloxone helps

2. Support the patient’s breathing with CPR







Ensure a clear airway
Place one hand on the patient’s chin, tilt head back and pinch
the nose closed
Place mouth over patient’s mouth to make a seal and give 2
slow breaths – the patient’s chest should rise
Give one breath every 5 seconds

Dreiling J. The Validation of Controlled Drug Prescriptions in Florida. https://s3.amazonaws.com/EliteCME_WebSite_2013/f/pdf/RPFL02VCI18.pdf. Accessed December 20, 2019.

Responding to an Overdose


3. Administer naloxone when signs of an overdose are
present




Naloxone should be given to restore respiratory drive

4. Stay until help arrives








You can expect naloxone to work within 3-5 minutes
Duration of action of naloxone is 30-90 minutes
Patients should be placed on their side
Do not slap or forcefully stimulate patients as it may cause
harm
Patients should not be placed in cold water, injected with
speed to wake them up or be forced to vomit the ingested
drug(s)

Dreiling J. The Validation of Controlled Drug Prescriptions in Florida. https://s3.amazonaws.com/EliteCME_WebSite_2013/f/pdf/RPFL02VCI18.pdf. Accessed December 20, 2019.

Avoiding Accidental
Overdoses


According to the World Health Organization, several
measures can be taken to avoid opioid overdose on a global
scale:







Increasing the availability of opioid dependence treatment, including
for those dependent on prescription opioids
Reduce irrational or inappropriate prescribing of opioids
Closely monitoring opioid prescribing and dispensing

Patient education for avoiding accidental overdoses






Never adjust your own dose – speak to your doctor if your pain is
uncontrolled
If a dose is missed, do not take extra medication to make up for the
missed dose
Do not mix with other medications such as benzodiazepines,
antidepressants, cocaine) and/or alcohol

Information Sheet on Opioid Overdose. World Health Organization. https://www.who.int/substance_abuse/information-sheet/en/. Updated August 2019. Accessed December 20, 2019.

The Pharmacist’s Role


According to the 2019 Florida statutes, Title XXIX,
chapter 381.887:


“An authorized health care practitioner may prescribe and
dispense an emergency opioid antagonist to a patient or
caregiver for use in accordance with this section, and
pharmacists may dispense an emergency opioid antagonist
pursuant to such a prescription or pursuant to a non-patientspecific standing order for an auto-injection delivery system or
intranasal application delivery system, which must be
appropriately labeled with instructions for use”

Treatment Resources
for Substance Abuse

Treatment Resources


Florida’s State Opioid Response Project (SOR) is administered through the
Office of Substance Abuse and Mental Health (SAMH) in the Florida
Department of Children and Families



The SAMH Program is the legislatively appointed state authority for
substance abuse, mental health, and methadone designation

https://www.myflfamilies.com/service-programs/samh/
Substance Abuse and Mental Health (SAMH). Florida Department of Children and Families. https://www.myflfamilies.com/service-programs/samh/. Accessed
December 20, 2019.

Treatment Resources
 Follow the “Get Help” link to find local treatment programs in your area

Substance Abuse and Mental Health (SAMH). Florida Department of Children and Families. https://www.myflfamilies.com/service-programs/samh/. Accessed
December 20, 2019.

Treatment Resources
https://www.samhsa.gov/

Substance Abuse and Mental Health (SAMH). Florida Department of Children and Families. https://www.myflfamilies.com/service-programs/samh/. Accessed
December 20, 2019.

Take Home Points





According to state law, C-II Rxs must be filled within 1 year
C-II Rxs may be faxed to the pharmacy to expedite the
filling of a Rx, however the original Rx must be presented
at time of dispensing
House Bill 21 limits quantity of CS that can be dispensed
and requires practitioners to indicate the type of pain which
correlates with the day supply






3 day supply: “acute pain”
7 day supply: “acute pain exception”
>7 days: “nonacute pain”

It is the standard of practice for the Florida Board of
Pharmacy to dispense control substance to patients with a
valid Rx for a legitimate medical purpose

Take Home Points









RPhs should take all necessary steps when validating an Rx
and refuse to fill it if professional judgment concerns cannot
be resolved as there is a corresponding responsibility when
dispensing such prescriptions
RPh must check E-FORCSE® for each new Rx dispensed no
later than close of next business day
Dispensers must notify E-FORCSE® by submitting a
Notification of Exemption from Reporting form if they will
not dispense CS
Patients with Rxs for opioids at doses >50 MME/d are at
higher risk for overdose – this calculation should be well
understood
Naloxone should be dispensed to any patient who could
possibly be experiencing an overdose – it will not have any
adverse effects if it is given and not truly needed

Questions


T/F: The main purpose of House Bill 21 is to limit acute pain to seven days
 False: House Bill 21 limits Rxs according to type of pain; for acute pain the limit is a 3
day supply. In order to get a 7 day supply, the prescriber must indicate “acute pain
exception”



T/F: If a prescriber does not include the required information on an Rx for a C-II CS, the
RPh is legally allowed to confirm with the prescriber and write it on the Rx
 True



T/F: SAMHSA is a government based helpline that provides information for Opioid
Treatment Programs nationwide
 True



T/F: The dose for Evzio® is 0.4 to 2 mg IV, IM, or SQ every 2-3 minutes
 False: Evzio® is the auto-injector formulation that administers 2 mg per 0.4 mL



T/F: All formulations of naloxone can be safely disposed of by flushing them down the toilet
 False: For intranasal dosage forms, used naloxone can be discarded with other solid
waste; for injectable dosage forms, used naloxone should be discarded in a sharps
container



T/F: RPhs are allowed to dispense a 3-day supply of a CS if the PDMP was not consulted
 True

Thank You!

Controlled Substance
Validation
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